CluenexRoivant Sciences ROIV
Roivant Sciences scores weak on business quality (3.7 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Roivant Sciences does
Roivant Sciences develops and acquires pharmaceutical assets through subsidiary companies known as vants. It generates revenue from product sales and licensing agreements.
- What it does best
Roivant builds and spins out drug development programs through its vant structure, holding a massive cash cushion of $4.2 billion with zero debt to fund clinical trials without dilution.
- The main risk
Cash burn is heavy, with free cash flow sitting at negative $821 million, forcing the company to rely on its reserves to fund ongoing drug development pipelines.
Quality, check by check
Scored against its own industry, from company filings.
Operating margins sit at negative 158.5% and FCF margin is deeply negative, reflecting heavy clinical trial spending before drugs reach commercial scale.
The moat rests on intellectual property and clinical development execution. With a gross margin at the 78th percentile of its sector, successful drug candidates carry high pricing power.
Revenue fell to $8.0 million, continuing a sharp multi-year decline from $61 million in 2023 as older products phase out and new ones await commercial scale.
With $4.2 billion in cash and zero debt, the balance sheet is pristine. However, free cash flow is negative $821 million, consuming reserves quickly.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
1 sold $36.5M outside pre-planned sales.
Our sealed record on ROIV
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Roivant Sciences scores weak on the Cluenex quality check (3.7 of 10), measured against its own industry. Profitability is weak, moat weak, growth slow and financial health strong.
In the last 90 days of SEC Form 4 filings: 1 sold $36.5M outside pre-planned sales.
Not scheduled yet.
See ROIV today
- Today's verdict on ROIV, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Roivant Sciences (ROIV)”, https://cluenex.com/stocks/roiv/, data as of Oct 10, 2026.